Results 261 to 270 of about 302,518 (309)
Some of the next articles are maybe not open access.
Treatment of chronic hepatitis B
Journal of Viral Hepatitis, 2005Summary. In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high incidence of resistance. Adefovir, which was recently approved has a comparable efficacy with a very low frequency of resistance.
Tarik, Asselah +2 more
openaire +5 more sources
Annals of Internal Medicine, 1988
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Excerpt To the Editor:Perrillo and colleagues (1) make an important contribution to the study of chronic hepatitis B treatment.
openaire +2 more sources
Progress in liver diseases, 1990
Chronic hepatitis B is said to affect at least 5 percent of the world's population and to be the chief cause of cirrhosis and hepatocellular carcinoma.1 The World Health Organization lists hepatiti...
S W, Schalm +2 more
openaire +3 more sources
Chronic hepatitis B is said to affect at least 5 percent of the world's population and to be the chief cause of cirrhosis and hepatocellular carcinoma.1 The World Health Organization lists hepatiti...
S W, Schalm +2 more
openaire +3 more sources
2016
A 45-year-old male Chinese university lecturer presented to his GP with malaise and dark urine. He was referred to the local infectious diseases clinic, and blood tests were as follows:
Navjyot Hansi +2 more
openaire +3 more sources
A 45-year-old male Chinese university lecturer presented to his GP with malaise and dark urine. He was referred to the local infectious diseases clinic, and blood tests were as follows:
Navjyot Hansi +2 more
openaire +3 more sources
BMJ, 2009
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Arthur C K Wong, Ching Lung Lai
openaire +1 more source
Clinical course and treatment of this infection common in Asia and the challenge of its global ...
Arthur C K Wong, Ching Lung Lai
openaire +1 more source
Treatment of chronic hepatitis B
Nature Clinical Practice Gastroenterology & Hepatology, 2006Treatment of chronic hepatitis B has improved substantially over the past five years. Pegylated interferon alpha2a and entecavir have been approved by the FDA and joined the armamentarium of therapies that includes inteferon alpha (IFN-alpha), lamivudine, and adefovir dipivoxil. Several key questions come to mind regarding treatment. Who should receive
Smruti R, Mohanty +2 more
openaire +2 more sources
Chronic hepatitis B virus infection
The Lancet, 2018Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage.
Wai-Kay, Seto +3 more
openaire +2 more sources
2018
Hepatitis B (HBV) is a viral infection of the liver and a common cause of chronic liver disease worldwide. An estimated 240 million people are affected by chronic hepatitis B (CHB) infection globally. In the United States, 850,000 to 2.2 million are estimated to be living with HBV.
Lindsay Meurer, Anthony Post
openaire +1 more source
Hepatitis B (HBV) is a viral infection of the liver and a common cause of chronic liver disease worldwide. An estimated 240 million people are affected by chronic hepatitis B (CHB) infection globally. In the United States, 850,000 to 2.2 million are estimated to be living with HBV.
Lindsay Meurer, Anthony Post
openaire +1 more source
Current Opinion in Gastroenterology, 2011
We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010.It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at ...
Hejun, Yuan, William M, Lee
openaire +2 more sources
We review here new developments in chronic hepatitis B (CHB) treatment, based on review of published articles between December 2009 and November 2010.It is estimated that two-thirds of US CHB patients have not been identified, evaluated and appropriately treated, largely due to lack of knowledge and awareness of CHB among medical professionals and at ...
Hejun, Yuan, William M, Lee
openaire +2 more sources
Management of chronic hepatitis B
Gastroenterology Clinics of North America, 2004Chronic hepatitis B (CHB) is a major worldwide cause of chronic liver disease and a significant public health issue. Three predominant clinical presentations are recognized: hepatitis B e antigen(HBeAg) or typical CHB, HBeAg-negative or atypical CHB, and inactive CHB.
Marc G, Ghany, Edward C, Doo
openaire +2 more sources